

CORPUS UTERI

Hospital Name/Address

Patient Name/Information

Type of Specimen _____

Histopathologic Type _____

Tumor Size _____

DEFINITIONS

Clinical	Primary Tumor (T)
<i>FIGO recommends surgical/pathologic staging.</i>	
<i>Clinical staging is done with 1971 FIGO as follows:</i>	
<input type="checkbox"/> _____	TNM FIGO Definitions
<input type="checkbox"/> (c)Tis	0 Carcinoma <i>in situ</i> . Histological findings suspicious of malignancy
<input type="checkbox"/> (c)T1	I Carcinoma is confined to the corpus including the isthmus
<input type="checkbox"/> (c)T1a	IA Length of the uterine cavity is 8 cm or less
<input type="checkbox"/> (c)T1b	IB Length of the uterine cavity is more than 8 cm
<i>Stage I cases should be subgrouped with regard to the histological type of the adenocarcinoma as follows:</i>	
<input type="checkbox"/> G1	Highly differentiated adenomatous carcinoma
<input type="checkbox"/> G2	Moderately differentiated adenomatous carcinoma with partly solid areas
<input type="checkbox"/> G3	Predominately solid or entirely undifferentiated carcinoma
<input type="checkbox"/> (c)T2	II Carcinoma has involved the corpus and the cervix, but has not extended outside the uterus
<input type="checkbox"/> (c)T3	III Carcinoma has extended outside the uterus, but not outside the true pelvis
<input type="checkbox"/> (c)T4	IV Carcinoma has extended outside the true pelvis or has obviously involved the mucosa of the bladder or rectum (Bullous edema as such does not permit a case to be allotted to stage IV)
<input type="checkbox"/> (c)T4a	IVA Spread of the growth to adjacent organs as urinary bladder, rectum, sigmoid colon, or small bowel
<i>Stage 0 cases should not be included in any therapeutic statistics.</i>	

Pathologic	Primary Tumor (T)
<input type="checkbox"/> _____	TNM FIGO Definitions
<input type="checkbox"/> TX	Primary tumor cannot be assessed
<input type="checkbox"/> T0	No evidence of primary tumor
<input type="checkbox"/> Tis	0 Carcinoma <i>in situ</i>
<input type="checkbox"/> T1	I Tumor confined to corpus uteri
<input type="checkbox"/> T1a	IA Tumor limited to endometrium
<input type="checkbox"/> T1b	IB Tumor invades less than one-half of the myometrium
<input type="checkbox"/> T1c	IC Tumor invades one-half or more of the myometrium
<input type="checkbox"/> T2	II Tumor invades cervix but does not extend beyond uterus
<input type="checkbox"/> T2a	IIA Tumor limited to the glandular epithelium of the endocervix. There is no evidence of connective tissue stromal invasion
<input type="checkbox"/> T2b	IIB Invasion of the stromal connective tissue of the cervix
<input type="checkbox"/> T3	III Local and/or regional spread as defined below
<input type="checkbox"/> T3a	IIIA Tumor involves serosa and/or adnexa (direct extension or metastasis) and/or cancer cells in ascites or peritoneal washings
<input type="checkbox"/> T3b	IIIB Vaginal involvement (direct extension or metastasis)
<input type="checkbox"/> T4	IVA Tumor invades bladder mucosa and/or bowel mucosa (bullous edema is not sufficient evidence to classify a tumor as T4)

Clinical	Pathologic	Regional Lymph Nodes (N)
<input type="checkbox"/> _____	<input type="checkbox"/> _____	NX Regional lymph nodes cannot be assessed
<input type="checkbox"/> _____	<input type="checkbox"/> _____	N0 No regional lymph node metastasis
<input type="checkbox"/> _____	<input type="checkbox"/> _____	N1 IIIC Regional lymph node metastases to pelvic and/or para-aortic lymph nodes

Clinical	Pathologic	Distant Metastasis (M)
<input type="checkbox"/> _____	<input type="checkbox"/> _____	MX Distant metastasis cannot be assessed
<input type="checkbox"/> _____	<input type="checkbox"/> _____	M0 No distant metastasis
<input type="checkbox"/> _____	<input type="checkbox"/> _____	M1 IVB Distant metastasis includes metastasis to intra-abdominal lymph nodes other than para-aortic, and/or inguinal lymph nodes; excludes metastasis to vagina, pelvic serosa, or adnexa

Biopsy of metastatic site performed ☐ Y ☐ N

Source of pathologic metastatic specimen _____ (continued on reverse side)

<i>Clinical</i>	<i>Pathologic</i>	Stage Grouping (AJCC/UICC/FIGO)				Notes
<input type="checkbox"/>	<input type="checkbox"/>	0	Tis	N0	M0	Additional Descriptors
<input type="checkbox"/>	<input type="checkbox"/>	I	T1	N0	M0	Lymphatic Vessel Invasion (L)
<input type="checkbox"/>	<input type="checkbox"/>	IA	T1a	N0	M0	LX Lymphatic vessel invasion cannot be assessed
<input type="checkbox"/>	<input type="checkbox"/>	IB	T1b	N0	M0	L0 No lymphatic vessel invasion
<input type="checkbox"/>	<input type="checkbox"/>	IC	T1c	N0	M0	L1 Lymphatic vessel invasion
<input type="checkbox"/>	<input type="checkbox"/>	II	T2	N0	M0	
<input type="checkbox"/>	<input type="checkbox"/>	IIA	T2a	N0	M0	Venous Invasion (V)
<input type="checkbox"/>	<input type="checkbox"/>	IIB	T2b	N0	M0	VX Venous invasion cannot be assessed
<input type="checkbox"/>	<input type="checkbox"/>	III	T3	N0	M0	V0 No venous invasion
<input type="checkbox"/>	<input type="checkbox"/>	IIIA	T3a	N	M0	V1 Microscopic venous invasion
<input type="checkbox"/>	<input type="checkbox"/>	IIIB	T3b	N0	M0	V2 Macroscopic venous invasion
<input type="checkbox"/>	<input type="checkbox"/>	IIIC	T1	N1	M0	
			T2	N1	M0	
			T3	N1	M0	
<input type="checkbox"/>	<input type="checkbox"/>	IVA	T4	Any N	M0	
<input type="checkbox"/>	<input type="checkbox"/>	IVB	Any T	Any N	M1	

Histologic Grade (G)

- ☐ GX Grade cannot be assessed
- ☐ G1 Well differentiated
- ☐ G2 Moderately differentiated
- ☐ G3-G4 Poorly differentiated or undifferentiated

Histopathology—Degree of Differentiation

Cases of carcinoma of the corpus should be grouped with regard to the degree of differentiation of the adenocarcinoma as follows:

- ☐ G1 5% or less of a non-squamous or non-morular solid growth pattern
- ☐ G2 6% to 50% of a non-squamous or non-morular solid growth pattern
- ☐ G3 more than 50% of a non-squamous or non-morular solid growth pattern

Residual Tumor (R)

- ☐ RX Presence of residual tumor cannot be assessed
- ☐ R0 No residual tumor
- ☐ R1 Microscopic residual tumor
- ☐ R2 Macroscopic residual tumor

Additional Descriptors

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.




- ☐ **m suffix** indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.
- ☐ **y prefix** indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy.
- ☐ **r prefix** indicates a recurrent tumor when staged after a disease-free interval, and is identified by the “r” prefix: rTNM.
- ☐ **a prefix** designates the stage determined at autopsy: aTNM.

Prognostic Indicators (if applicable)

CORPUS UTERI

ILLUSTRATION

Indicate on diagram primary tumor and regional nodes involved.



Physician's Signature _____ Date _____